Verastem Price Target Raised to $15 After Promising VS-7375 and RAMP-205 Results
VSTM•RBC Capital raised its price target for Verastem to $15.00 from its then-trading price of $4.33 after preliminary TARGET-D 101 Phase 1/2 data showed promising safety and activity of VS-7375 in KRAS G12D-mutated solid tumors. Updated RAMP-205 trial results also reported encouraging efficacy in first-line metastatic pancreatic cancer.
1. Analyst Price Target Revision
RBC Capital increased its price target for Verastem to $15.00 from $4.33, signaling stronger confidence in the company’s growth trajectory. At the time, Verastem’s market capitalization stood at approximately $296 million, underscoring the scale of the potential upside.
2. Clinical Trial Updates
Preliminary findings from the TARGET-D 101 Phase 1/2 trial indicated that VS-7375 demonstrated favorable safety and antitumor activity in patients with KRAS G12D-mutated solid tumors. Updated results from the RAMP-205 study also showed encouraging efficacy of avutometinib and defactinib in combination with chemotherapy for first-line metastatic pancreatic cancer patients.
